sarpogrelate has been researched along with Apoplexy in 3 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed a double-blind, controlled clinical-pharmacological study to investigate the antiplatelet efficacy of sarpogrelate, a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist, in patients with ischemic stroke, using a new assessment system employing combinations of 5-HT and epinephrine as agonists." | 9.12 | Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. ( Kondo, K; Nishimaru, K; Ozaki, Y; Satoh, K; Uchiyama, S, 2007) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| " We performed a double-blind, controlled clinical-pharmacological study to investigate the antiplatelet efficacy of sarpogrelate, a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist, in patients with ischemic stroke, using a new assessment system employing combinations of 5-HT and epinephrine as agonists." | 5.12 | Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. ( Kondo, K; Nishimaru, K; Ozaki, Y; Satoh, K; Uchiyama, S, 2007) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Weber, R | 1 |
| Diener, HC | 1 |
| Uchiyama, S | 1 |
| Ozaki, Y | 1 |
| Satoh, K | 1 |
| Kondo, K | 1 |
| Nishimaru, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.[NCT00147303] | Phase 3 | 46 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarpogrelate and Apoplexy
| Article | Year |
|---|---|
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
1 trial available for sarpogrelate and Apoplexy
| Article | Year |
|---|---|
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Topics: Administration, Oral; Aged; Blood Platelets; Brain Ischemia; Dose-Response Relationship, Drug; Doubl | 2007 |
1 other study available for sarpogrelate and Apoplexy
| Article | Year |
|---|---|
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |